# K J Ewer

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 115 papers | 18,881 citations | 44042 48 h-index | 30058 103 g-index |
| 121 all docs | 121 docs citations | 121 times ranked | 22376 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe, The, 2022, 3, e11-e20. | 3.4 | 25 |
| 2 | Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. Frontiers in Immunology, 2022, 13, 795463. | 2.2 | 6 |
| 3 | Vaccines against SARS-CoV-2. , 2022, , 201-222. | | 0 |
| 4 | CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, . | 2.3 | 6 |
| 5 | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, . | 2.3 | 26 |
| 6 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111. | 6.3 | 3,887 |
| 7 | Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288. | 15.2 | 265 |
| 8 | T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278. | 15.2 | 473 |
| 9 | Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013â€“16 West Africa epidemic. Nature Communications, 2021, 12, 1153. | 5.8 | 10 |
| 10 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891. | 6.3 | 979 |
| 11 | Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies. Vaccines, 2021, 9, 262. | 2.1 | 3 |
| 12 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362. | 6.3 | 540 |
| 13 | Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet, The, 2021, 397, 1809-1818. | 6.3 | 253 |
| 14 | A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. Nature Communications, 2021, 12, 4636. | 5.8 | 31 |
| 15 | Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS). Vaccines, 2021, 9, 851. | 2.1 | 6 |
| 16 | Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485. | 2.1 | 190 |
| 17 | A three-antigen Plasmodium falciparum DNA primeâ€"Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naÃ¯ve adults. PLoS ONE, 2021, 16, e0256980. | 1.1 | 10 |
| 18 | AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T <sub>H</sub> 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211. | 5.8 | 80 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040. | 15.2 | 900 |
| 20 | Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990. | 6.3 | 214 |
| 21 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478. | 6.3 | 2,080 |
| 22 | Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993. | 6.3 | 1,196 |
| 23 | Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. Journal of Experimental Medicine, 2020, 217, . | 4.2 | 31 |
| 24 | The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. Immunology, 2020, 160, 223-232. | 2.0 | 86 |
| 25 | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infectious Diseases, The, 2020, 20, 816-826. | 4.6 | 182 |
| 26 | Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. Journal of Infectious Diseases, 2019, 219, 1187-1197. | 1.9 | 59 |
| 27 | Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines, 2019, 7, 40. | 2.1 | 19 |
| 28 | Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines, 2019, 7, 33. | 2.1 | 23 |
| 29 | OC 8552â€…EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5â€“17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO. BMJ Global Health, 2019, 4, A13.1-A13. | 2.0 | 0 |
| 30 | Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. Cell Reports, 2019, 29, 2537-2545.e3. | 2.9 | 7 |
| 31 | Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Scientific Reports, 2018, 8, 3390. | 1.6 | 34 |
| 32 | First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. PLoS ONE, 2018, 13, e0208328. | 1.1 | 53 |
| 33 | CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. Frontiers in Immunology, 2018, 9, 1660. | 2.2 | 26 |
| 34 | Prime and target immunization protects against liver-stage malaria in mice. Science Translational Medicine, 2018, 10, . | 5.8 | 68 |
| 35 | Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. Npj Vaccines, 2018, 3, 49. | 2.9 | 51 |
| 36 | Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man. Vaccines, 2018, 6, 43. | 2.1 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. Vaccines, 2018, 6, 50. | 2.1 | 54 |
| 38 | Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. Journal of Immunology, 2018, 201, 1315-1326. | 0.4 | 30 |
| 39 | Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine. Infection and Immunity, 2017, 85, . | 1.0 | 16 |
| 40 | Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. Molecular Therapy, 2017, 25, 547-559. | 3.7 | 34 |
| 41 | A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160295. | 1.8 | 33 |
| 42 | Cryopreservation-related loss of antigen-specific IFNÎ³ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. Vaccine, 2017, 35, 1898-1906. | 1.7 | 40 |
| 43 | Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032. | 1.4 | 67 |
| 44 | Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-Mâ„¢. Vaccine, 2017, 35, 6208-6217. | 1.7 | 27 |
| 45 | An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens. Scientific Reports, 2017, 7, 17011. | 1.6 | 15 |
| 46 | Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. Frontiers in Immunology, 2017, 8, 1551. | 2.2 | 23 |
| 47 | IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES. BMJ Global Health, 2017, 2, A30.3-A31. | 2.0 | 0 |
| 48 | Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. PLoS ONE, 2016, 11, e0167951. | 1.1 | 46 |
| 49 | Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. Open Forum Infectious Diseases, 2016, 3, ofw031. | 0.4 | 13 |
| 50 | Safety and Immunogenicity of Novel Adenovirus Type 26â€“ and Modified Vaccinia Ankaraâ€“Vectored Ebola Vaccines. JAMA - Journal of the American Medical Association, 2016, 315, 1610. | 3.8 | 266 |
| 51 | Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 2016, 24, 1470-1477. | 3.7 | 52 |
| 52 | Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 2016, 41, 47-54. | 2.4 | 137 |
| 53 | Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01<sub>B</sub>With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of Infectious Diseases, 2016, 214, 772-781. | 1.9 | 96 |
| 54 | A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646. | 13.9 | 295 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfLIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice. PLoS ONE, 2015, 10, e0144515. | 1.1 | 5 |
| 56 | Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086. | 1.9 | 110 |
| 57 | Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific Reports, 2015, 5, 11820. | 1.6 | 49 |
| 58 | Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5. | 5.8 | 113 |
| 59 | Progress with viral vectored malaria vaccines: A multi-stage approach involving â€œunnatural immunityâ€• Vaccine, 2015, 33, 7444-7451. | 1.7 | 53 |
| 60 | Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BNÂ® FILO in healthy UK adults. Journal of Infection, 2015, 71, 688. | 1.7 | 0 |
| 61 | Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells. PLoS ONE, 2015, 10, e0119880. | 1.1 | 17 |
| 62 | Heterologous Prime-Boost Schedules of Replication-Defective Adenovirus Serotype 26 and Modified Vaccinia Virus Ankara Vector Vaccines Expressing Ebola Virus Glycoprotein Are Immunogenic and Well Tolerated in Healthy Adults. Open Forum Infectious Diseases, 2015, 2, . | 0.4 | 1 |
| 63 | Correction for NÃ©biÃ© et al., Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Vaccine Journal, 2014, 21, 1376-1376. | 3.2 | 0 |
| 64 | Development of an in vitro Plasmodium parasite killing assay for the evaluation of cell-mediated immune responses following vaccination with pre-erythrocytic malaria vaccine candidates. Malaria Journal, 2014, 13, . | 0.8 | 1 |
| 65 | Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults. Malaria Journal, 2014, 13, . | 0.8 | 0 |
| 66 | Co-infection with Schistosoma haematobium modulates the gene expression profile of malaria infection in schoolchildren in Gabon. Malaria Journal, 2014, 13, . | 0.8 | 0 |
| 67 | Analysis of human <scp>B</scp>â€cell responses following <scp>C</scp>h<scp>A</scp>d63â€<scp>MVA MSP</scp>1 and <scp>AMA</scp>1 immunization and controlled malaria infection. Immunology, 2014, 141, 628-644. | 2.0 | 43 |
| 68 | Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children. Malaria Journal, 2014, 13, . | 0.8 | 0 |
| 69 | Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Vaccine Journal, 2014, 21, 901-903. | 3.2 | 12 |
| 70 | Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations. Molecular Therapy, 2014, 22, 1992-2003. | 3.7 | 49 |
| 71 | Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. PLoS ONE, 2014, 9, e107903. | 1.1 | 65 |
| 72 | A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS ONE, 2014, 9, e115161. | 1.1 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature Communications, 2013, 4, 2836. | 5.8 | 256 |
| 74 | Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. Journal of Immunology, 2013, 190, 1135-1147. | 0.4 | 23 |
| 75 | Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. PLoS ONE, 2013, 8, e57726. | 1.1 | 64 |
| 76 | Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. Journal of Infectious Diseases, 2012, 205, 772-781. | 1.9 | 194 |
| 77 | Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Science Translational Medicine, 2012, 4, 115ra2. | 5.8 | 257 |
| 78 | ChAd63-MVAâ€“vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. Molecular Therapy, 2012, 20, 2355-2368. | 3.7 | 196 |
| 79 | Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. PLoS ONE, 2012, 7, e31208. | 1.1 | 157 |
| 80 | Clinical Evaluation Of New Viral Vectored Vaccines Targeting The Plasmodium Falciparum Blood-Stage Antigens; Msp1 And Ama1. Journal of Infection, 2011, 63, 492-493. | 1.7 | 0 |
| 81 | Viral vectors as vaccine platforms: deployment in sight. Current Opinion in Immunology, 2011, 23, 377-382. | 2.4 | 188 |
| 82 | Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. Molecular Therapy, 2011, 19, 2269-2276. | 3.7 | 156 |
| 83 | Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. Clinical Infectious Diseases, 2011, 52, 1-7. | 2.9 | 424 |
| 84 | Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS ONE, 2011, 6, e22271. | 1.1 | 84 |
| 85 | Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83. | 2.4 | 184 |
| 86 | Gene expression profiling and antigen mining of the tuberculin production strain Mycobacterium bovis AN5. Veterinary Microbiology, 2009, 133, 272-277. | 0.8 | 5 |
| 87 | Potency assays for novel T-cell-inducing vaccines against malaria. Current Opinion in Molecular Therapeutics, 2009, 11, 72-80. | 2.8 | 23 |
| 88 | Screening of Highly Expressed Mycobacterial Genes Identifies Rv3615c as a Useful Differential Diagnostic Antigen for theMycobacterium tuberculosisComplex. Infection and Immunity, 2008, 76, 3932-3939. | 1.0 | 95 |
| 89 | Characterization of two in vivo-expressed methyltransferases of the Mycobacterium tuberculosis complex: antigenicity and genetic regulation. Microbiology (United Kingdom), 2008, 154, 1059-1067. | 0.7 | 13 |
| 90 | Is Interleukin-4Î´3 Splice Variant Expression in Bovine Tuberculosis a Marker of Protective Immunity?. Infection and Immunity, 2007, 75, 3006-3013. | 1.0 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | T-Cell-Based Diagnosis of Neonatal Multidrug-Resistant Latent Tuberculosis Infection. Pediatrics, 2007, 119, e1-e5. | 1.0 | 41 |
| 92 | Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1â€“IFN-Î³ Assay Receive Preventive Therapy?. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 199-199. | 2.5 | 1 |
| 93 | Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. Journal of Infection, 2007, 54, e169-e174. | 1.7 | 22 |
| 94 | Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. Leukemia, 2006, 20, 379-381. | 3.3 | 17 |
| 95 | Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure toMycobacterium tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 831-839. | 2.5 | 196 |
| 96 | Repeated tuberculin testing does not induce false positive ELISPOT results. Thorax, 2006, 61, 180-180. | 2.7 | 44 |
| 97 | Antigen Mining with Iterative Genome Screens Identifies Novel Diagnostics for the Mycobacterium tuberculosis Complex. Vaccine Journal, 2006, 13, 90-97. | 3.2 | 19 |
| 98 | Ex Vivo Characterization of Early Secretory Antigenic Target 6-Specific T Cells at Sites of Active Disease in Pleural Tuberculosis. Clinical Infectious Diseases, 2005, 40, 184-187. | 2.9 | 155 |
| 99 | Enzyme-linked Immunospot and Tuberculin Skin Testing to Detect Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 1161-1168. | 2.5 | 117 |
| 100 | Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet, The, 2005, 366, 1443-1451. | 6.3 | 266 |
| 101 | T Cellâ€“Based Tracking of Multidrug Resistant Tuberculosis Infection after Brief Exposure. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 288-295. | 2.5 | 131 |
| 102 | Characterization of a Mycobacterium tuberculosis Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles. Journal of Immunology, 2004, 173, 1966-1977. | 0.4 | 82 |
| 103 | Evaluation of T-Cell Responses to Novel RD1- and RD2-Encoded Mycobacterium tuberculosis Gene Products for Specific Detection of Human Tuberculosis Infection. Infection and Immunity, 2004, 72, 2574-2581. | 1.0 | 75 |
| 104 | Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study. Lancet, The, 2004, 364, 2196-2203. | 6.3 | 353 |
| 105 | Early Diagnosis of Subclinical Multidrug-Resistant Tuberculosis. Annals of Internal Medicine, 2004, 140, 709. | 2.0 | 59 |
| 106 | Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet, The, 2003, 361, 1168-1173. | 6.3 | 578 |
| 107 | Diagnosis of tuberculosis. Lancet, The, 2003, 361, 2081-2082. | 6.3 | 3 |
| 108 | Diagnosis of tuberculosis. Lancet, The, 2003, 361, 2082-2083. | 6.3 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. Aids, 2002, 16, 2285-2293. | 1.0 | 276 |
| 110 | Enumeration of T Cells Specific for RD1â€Encoded Antigens Suggests a High Prevalence of LatentMycobacterium tuberculosisInfection in Healthy Urban Indians. Journal of Infectious Diseases, 2001, 183, 469-477. | 1.9 | 335 |
| 111 | Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). SSRN Electronic Journal, 0, , . | 0.4 | 36 |
| 112 | Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. SSRN Electronic Journal, 0, , . | 0.4 | 10 |
| 113 | Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. SSRN Electronic Journal, 0, , . | 0.4 | 6 |
| 114 | Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). SSRN Electronic Journal, 0, , . | 0.4 | 23 |
| 115 | High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-Mâ„¢, with Seasonal Administration to Children in Burkina Faso. SSRN Electronic Journal, 0, , . | 0.4 | 12 |